시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 이상지질혈증 치료 시장 보고서(2025년)
Lipid Disorder Treatment Global Market Report 2025
상품코드 : 1825788
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

이상지질혈증 치료 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 2029년에는 CAGR 11.8%로 188억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 비만과 고콜레스테롤 사례의 증가, 심혈관질환의 유병률 증가, 심장병의 원인이 되는 고콜레스테롤 발생 증가, 안전하고 효율적인 치료법에 대한 수요 증가, 과도한 음주와 흡연에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 의약품 개발의 기술 발전, 제품 혁신, 사업 확장에 대한 투자 증가, 치료 시설의 기술 발전, 임상 발전 등이 있습니다.

향후 5년간 11.8%의 성장률 전망은 지난번 예측보다 0.5% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 인상은 프랑스와 이탈리아에서 조달하는 PCSK9 억제제 및 지단백질 아펠레시스 시스템의 비용을 상승시키고, 심혈관질환 관리 비용을 악화시키고, 첨단 치료에 대한 접근성을 제한함으로써 미국 환자들에게 부담을 줄 가능성이 높습니다. 또한, 상호 관세와 무역 긴장의 고조와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

이상지질혈증 치료 시장의 예상 성장은 비만과 고콜레스테롤 유병률의 증가로 인해 촉진될 것으로 예상됩니다. 과도한 체지방 축적을 특징으로 하는 비만과 혈중 콜레스테롤 수치 상승을 나타내는 고콜레스테롤은 심각한 건강 위험을 초래하며, 건강에 해로운 식습관, 좌식 생활습관, 유전적 소인, 환경적 영향 등 다양한 요인에 의해 증가 추세에 있습니다. 이상지질혈증 치료는 생활습관 개선, 체중 관리 전략, 환자 교육, 다학제적 치료와 함께 약리학적 중재를 통해 비만과 고콜레스테롤 관리에 중요한 역할을 하고 있습니다. 예를 들어, 세계비만연맹이 발표한 World Obesity Atlas 2022에 따르면, 2030년까지 전 세계적으로 10억 명이 비만과 함께 생활하고, 2035년까지 그 수가 40억 명, 즉 세계 인구의 51%까지 확대될 것으로 예측하고 있습니다. 따라서 비만과 고콜레스테롤증 사례의 증가는 이상지질혈증 치료 시장의 성장을 촉진하는 주요 요인입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Lipid disorder treatment encompasses a holistic approach involving lifestyle adjustments, medications, and regular monitoring to manage conditions such as high cholesterol and triglycerides. The goal is to mitigate the risk of atherosclerosis and its associated complications, including heart disease and stroke.

Key medications used in lipid disorder treatment include atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, and others. Atorvastatin, classified as an HMG-CoA reductase inhibitor, is utilized for various lipid disorders, including familial combined hyperlipidemia, familial defective apolipoprotein B-100, familial dysbetalipoproteinemia, familial hypertriglyceridemia, heterozygous familial hypercholesterolemia, among others. This medication is made available through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The lipid disorder treatment market research report is one of a series of new reports from The Business Research Company that provides lipid disorder treatment market statistics, including lipid disorder treatment industry global market size, regional shares, competitors with a lipid disorder treatment market share, detailed lipid disorder treatment market segments, market trends and opportunities, and any further data you may need to thrive in the lipid disorder treatment industry. This lipid disorder treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lipid disorder treatment market size has grown rapidly in recent years. It will grow from $10.69 billion in 2024 to $12.06 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increase in adoption of sedentary lifestyle, rise in working population, rise in awareness regarding the disease and treatment, increase in on-the-desk jobs, growth of familial combined hyperlipidemia incidence.

The lipid disorder treatment market size is expected to see rapid growth in the next few years. It will grow to $18.82 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to growing cases of obesity and high cholesterol, increase in prevalence of cardiovascular diseases, growing occurrence of high cholesterol causing heart diseases, rise in the demand for safe and efficient treatments, excessive consumption of alcohol and smoking. Major trends in the forecast period include technological advancements in drug development, product innovation, increase in investments in business expansion, technological advancement in the treatment facilities, clinical advancements.

The forecast of 11.8% growth over the next five years reflects a modest reduction of 0.5% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. patients by driving up the cost of PCSK9 inhibitors and lipoprotein apheresis systems sourced from France and Italy, exacerbating cardiovascular disease management expenses and limiting access to advanced therapies. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the lipid disorder treatment market is expected to be propelled by the increasing prevalence of obesity and high cholesterol. Obesity, characterized by excessive body fat accumulation, and high cholesterol, denoting elevated cholesterol levels in the blood, pose significant health risks and are on the rise due to various factors including unhealthy diets, sedentary lifestyles, genetic predispositions, and environmental influences. Lipid disorder treatment plays a crucial role in managing obesity and high cholesterol by employing pharmacological interventions alongside lifestyle modifications, weight management strategies, patient education, and multidisciplinary care. For instance, according to the World Obesity Atlas 2022 published by the World Obesity Federation, it is projected that by 2030, one billion people globally will be living with obesity, with that number escalating to 4 billion people, or 51% of the global population, by 2035. Hence, the escalating cases of obesity and high cholesterol are key drivers fueling the growth of the lipid disorder treatment market.

Major companies in this market are focusing on developing innovative therapies to address the need for more effective and targeted treatments for managing high cholesterol levels. One such example is the development of proprotein convertase subtilisin type 9 (PCSK9) inhibitors, which enhance the removal of LDL cholesterol from the bloodstream, thus reducing the risk of cardiovascular events in high-risk patients. For instance, in March 2024, Regeneron Pharmaceuticals Inc. received FDA approval for Praluent (alirocumab) injection to treat heterozygous familial hypercholesterolemia (HeFH) in children aged 8 and above. This medication blocks the binding of PCSK9 to the LDL receptor, increasing the quantity of LDL receptors on liver cell surfaces and facilitating the clearance of LDL cholesterol from the bloodstream.

In July 2023, Eli Lilly and Company's acquisition of Versanis contribute to bolstering companies' portfolios in the cardiometabolic disease space, particularly in the obesity drug pipeline. Versanis, a clinical-stage biopharmaceutical company specializing in treating cardiometabolic diseases, enhances Lilly's capabilities in addressing the challenges posed by obesity and related disorders.

Major companies operating in the lipid disorder treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., AstraZeneca Plc, Fresenius SE & Co. KGaA, Abbott Laboratories Inc., Novartis AG, GlaxoSmithKline Plc, Wockhardt Ltd., Eli Lilly and Company, Amgen Inc., Boehringer-Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Kaneka Corporation, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Kowa Pharmaceuticals America Inc., Concord Biotech Limited, Biocon Ltd., Ranbaxy Laboratories Limited.

North America was the largest region in the lipid disorder treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid disorder treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the lipid disorder treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lipid disorder treatment market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, lifestyle counseling, medication management, and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The lipid disorder treatment market also includes sales of fibrates, niacin, bile acid sequestrants and omega-3 fatty acids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lipid Disorder Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lipid disorder treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for lipid disorder treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The lipid disorder treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Lipid Disorder Treatment Market Characteristics

3. Lipid Disorder Treatment Market Trends And Strategies

4. Lipid Disorder Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Lipid Disorder Treatment Growth Analysis And Strategic Analysis Framework

6. Lipid Disorder Treatment Market Segmentation

7. Lipid Disorder Treatment Market Regional And Country Analysis

8. Asia-Pacific Lipid Disorder Treatment Market

9. China Lipid Disorder Treatment Market

10. India Lipid Disorder Treatment Market

11. Japan Lipid Disorder Treatment Market

12. Australia Lipid Disorder Treatment Market

13. Indonesia Lipid Disorder Treatment Market

14. South Korea Lipid Disorder Treatment Market

15. Western Europe Lipid Disorder Treatment Market

16. UK Lipid Disorder Treatment Market

17. Germany Lipid Disorder Treatment Market

18. France Lipid Disorder Treatment Market

19. Italy Lipid Disorder Treatment Market

20. Spain Lipid Disorder Treatment Market

21. Eastern Europe Lipid Disorder Treatment Market

22. Russia Lipid Disorder Treatment Market

23. North America Lipid Disorder Treatment Market

24. USA Lipid Disorder Treatment Market

25. Canada Lipid Disorder Treatment Market

26. South America Lipid Disorder Treatment Market

27. Brazil Lipid Disorder Treatment Market

28. Middle East Lipid Disorder Treatment Market

29. Africa Lipid Disorder Treatment Market

30. Lipid Disorder Treatment Market Competitive Landscape And Company Profiles

31. Lipid Disorder Treatment Market Other Major And Innovative Companies

32. Global Lipid Disorder Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Lipid Disorder Treatment Market

34. Recent Developments In The Lipid Disorder Treatment Market

35. Lipid Disorder Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기